

 <b>Shared health</b> <b>Soins communs</b> Manitoba	<b>X08- MEDICATIONS (SECTION M) CHANGE TRACKING</b>	
	Version date: 2024-01-20	Publication Date: 2024-02-13

<b>M01 - ADENOSINE</b>
<p>2023-07-24:</p> <ul style="list-style-type: none"> <li>Revised administration table presents information for scope / route / dose more clearly</li> </ul> <p>2022-06-25:</p> <ul style="list-style-type: none"> <li>Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)</li> </ul> <p>2022-03-12:</p> <ul style="list-style-type: none"> <li>Minor reformatting (removal of change tracking from care map)</li> </ul> <p>2021-10-19:</p> <ul style="list-style-type: none"> <li>Minor reformatting</li> </ul> <p>2021-05-18:</p> <ul style="list-style-type: none"> <li>Replacement of colored boxes by scope of work statement &amp; icons</li> <li>New standing &amp; interim order statements</li> <li>Reformatting</li> </ul> <p>2020-06-15</p> <ul style="list-style-type: none"> <li>Clarification of indications &amp; contraindications</li> <li>Reformatting</li> </ul> <p>2017-03-20:</p> <ul style="list-style-type: none"> <li>Original version</li> </ul>
<b>M02.1 - ACETAMINOPHEN</b>
<p>2023-11-09:</p> <ul style="list-style-type: none"> <li>Correction of pediatric dosing information</li> </ul> <p>2023-10-17:</p> <ul style="list-style-type: none"> <li>Correction of dosing information (12 months up to 12 years)</li> </ul> <p>2023-07-24:</p> <ul style="list-style-type: none"> <li>Revised administration table presents information for scope / route / dose more clearly</li> </ul> <p>2022-06-25:</p> <ul style="list-style-type: none"> <li>Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)</li> </ul> <p>2022-05-03:</p> <ul style="list-style-type: none"> <li>Rectal dosing route removed</li> </ul> <p>2022-03-12:</p> <ul style="list-style-type: none"> <li>Minor reformatting (removal of change tracking from care map)</li> </ul> <p>2021-10-19:</p> <ul style="list-style-type: none"> <li>Minor reformatting</li> </ul> <p>2021-05-18:</p> <ul style="list-style-type: none"> <li>Addition of scope of work and standing order statements</li> </ul>

- Revised age range for dosing & revised PR dosing
- Reformatting

2020-06-16:

- Replaces M02
- Contraindication added for liver failure
- Removal of naproxen
- Reformatting

2018-02-03:

- Original version

### **M02.2 - IBUPROFEN**

2023-07-24:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-25:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-12:

- Minor reformatting (removal of change tracking from care map)

2021-10-19:

- Minor reformatting

2021-05-18:

- Addition of scope of work and standing order statements
- Pregnancy added to contraindications
- Reformatting

2020-04-14:

- Replaces M02
- Removal of naproxen
- Reformatting

2018-02-03:

- Original version

### **M03.1 - MORPHINE**

2023-12-13:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-07-24:

- Revised administration table presents information for scope / route / dose more clearly

2022-11-27:

- Removal of dyspnea due to pulmonary edema as indication

2022-06-25:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-10-20:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Reformatting

2020-07-07:

- Separation of different opioids into separate documents
- Removal of hydromorphone
- Revised dosing & contraindications

2017-03-28:

- Original version

### **M03.2 - FENTANYL**

2023-12-13:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-07-24:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-25:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Providers with primary work scope (PCP) can now administer parenterally
- Switch to parenteral route required if multiple doses required (max 2 IN doses)
- Revised dosing (range) for IM / IV / IO administration
- Consideration of smaller starting doses if opioid naïve or advanced age

2022-05-03:

- Mandatory IV access added

2022-03-12:

- Minor reformatting (removal of change tracking from care map)

2021-11-17:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Intranasal administration now allowed
- Reformatting

2020-07-07:

- Revised dosing & contraindications
- Fentanyl by all routes combined into one document
- New contraindications for IN & IM routes

2017-03-28:

- Original version

### **~~M03.3~~ - HYDROMORPHONE**

2022-03-13:

- Deleted (replaced by G02)

~~2017-03-28:~~

- ~~• Original version~~

#### M04.1 – DIMENHYDRINATE

2023-07-24:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-25:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2021-11-17:

- Minor reformatting

2021-05-19

- Addition of scope of work and standing order statements
- Reformatting

2020-06-15:

- Change to weight-based dosing in children
- Reformatting

2017-03-23:

- Original version

#### M04.2 – METOCLOPRAMIDE

2023-07-24:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-25:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-11-17:

- Minor reformatting

2020-06-15:

- Addition of scope of work and standing order statements
- Addition of bowel obstruction to contraindications
- Adolescent dose range adjusted
- Change to weight-based dosing for children
- Reformatting

2017-3-22:

- Original version

#### M04.3 - ONDANSETRON

2023-09-05:

- Removal of ketorolac as contraindication
- Revised administration table presents information for scope / route / dose more clearly

2022-06-26:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-21:

- Minor reformatting

2020-06-15:

- Addition of scope of work and standing order statements
- Change to weight-based dosing in adolescents
- Pediatric dose 1-10 years removed
- Removed from PCP scope of practice (due to ECG contraindications)
- New contraindications
- Reformatting

2017-03-23:

- Original version

#### **M05.1 - EPINEPHRINE FOR ANAPHYLAXIS**

2023-12-14:

- High-alert warning removed

2023-11-18:

- Correction of pediatric dosing information

2023-09-29:

- Correction of dosing information for 12 months up to 17 years

2023-07-19:

- Revised administration table presents information for scope / route / dose more clearly
- High-alert warning added

2022-06-26:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2021-11-25:

- Dosing table (identical to E03) added
- Dosing frequency changed to every 5 to 15 minutes as required
- Revised indication to align with E03 Care map
- Removal of IV bolus dosing as bolus dosing associated with increased errors & complications, and infusions not available until pumps are available

2021-05-19:

- Addition of scope of work and standing order statements
- Addition of high-alert warning
- Reformatting

2020-05-13:

- Increased IM & number of repeat doses
- Removal of adolescent and pediatric IV administration
- Providers at the PCP level and above can repeat as many times as required at 15-minute intervals.

2017-07-17:

- Original version

#### **M05.2 - EPINEPHRINE FOR CARDIAC ARREST**

2024-12-14:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-07-19:

- Revised administration table presents information for scope / route / dose more clearly
- High-alert warning added

2022-06-26:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Increased maximum dose for pediatric arrest
- Early administration recommended in asystole / PEA (as per HSF 2020 guidelines)
- Explicit instruction on volume, flush and elevating arm

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-25:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Reformatting

2020-07-09:

- Reformatting / no content change

2017-07-17

- Original version

### **M05.3 - EPINEPHRINE FOR REFRACTORY ASTHMA**

2023-12-14:

- High-alert warning removed

2023-07-23:

- Revised administration table presents information for scope / route / dose more clearly
- High-alert warning added
- Maximum number of doses reduced to two
- Title change to include word “refractory”

2022-11-26:

- Revised indication wording to align with E06
- Addition of heart failure & myocardial ischemia to contraindications

2022-06-27:

- Reimplemented with more specific indication and contraindications

### **M05.4 - EPINEPHRINE FOR CROUP**

2023-12-14:

- High-alert warning removed

2023-07-23:

- Revised administration table presents information for scope / route / dose more clearly
- High-alert warning added

2022-12-02:

- Reduced dosing frequency

2022-09-08:

- Can be administered during COVID pandemic

2022-06-26:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-11-04:

- Minor reformatting
- Dosing frequency decreased to every 15 minutes

2021-11-04:

- New document

#### **M06.1 - GLUCOSE**

2023-07-20:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-26:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-25:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Increase in repeat dosing from once to “as required”
- Inclusion of glucose content of various preparations
- Reformatting

2017-03-23:

- Original version

#### **M06.2 - DEXTROSE**

2023-12-13:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-07-20:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-26:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Further clarification regarding empiric treatment when POCG testing is not promptly available

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-25:

- Minor reformatting

2021-06-11:

- Addition of scope of work and standing order statements
- Switch to 10% dextrose for routine use
- Addition of high-alert warning for infants & newborns
- Slower rate of administration for infants
- Reformatting

2017-06-19:

- Original version

### **M06.3 - GLUCAGON**

2023-07-20:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-26:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-22:

- Providers with the basic work scope must consult with OLMS

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-11-25:

- Removed repetitive wording from indications section
- Added missing title IV/IO to dosing section

2021-10-25:

- Minor reformatting
- Revised - refractory anaphylaxis removed as indication

2021-06-11:

- Addition of scope of work and standing order statements
- Clarification of dosing for refractory anaphylaxis
- Intranasal administration now allowed
- Reformatting

2021-02-19

- Indication of refractory anaphylaxis added

2020-04-15:

- IM & IV administration now in scope for PCP
- Caution regarding IM route added

2017-06-19:

- Original version

### **M06.4 - GLUCAGON NASAL POWDER**

2023-07-22:

- Revised administration table presents information for scope / route / dose more clearly

2023-05-02:



- New

### **M07.1 - MIDAZOLAM**

2023-12-14:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-07-15:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-26:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-04-06:

- Removal of CNS depression as a contraindication

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-11-05:

- Minor reformatting
- Clarification that IV dose is to be titrated to effect

2021-06-08:

- Airway maintenance added at PCP level with consultation with OLMS
- Correction of dosing at 10 years & older
- Simplification of IV (IO) dosing

2021-05-19:

- Addition of scope of work and standing order statements
- Intranasal administration now allowed Clarification of choice of route for active seizures
- More detail regarding titration of dosing for various indications
- More detail regarding IO access for various indications
- Dosing changes
- Reformatting

2020-05-11:

- Consolidation of previous documents M07.1; M07.2; and M07.3 into single protocol
- Decreased dosing for intravenous administration
- IM administration now in scope for PCP
- IV & IO administration now in scope for PCP for specific indications

2017-06-19

- Original version

### **M07.5 - LORAZEPAM**

2023-07-18:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-26:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-25:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Reformatting

2020-05-28:

- Removal of parenteral routes of administration
- Revised dosing
- Reformatting

2017-06-19

- Original version

#### **M09 - FUROSEMIDE**

2023-07-18:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-26:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Indication refined to require evidence of pulmonary edema
- Dosing simplified

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-25:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Reformatting

2020-08-20:

- Revised dosing

2017-04-03:

- Original version

#### **M10 — HYPERKALEMIA THERAPY**

2024-02-13:

- Deleted (replaced by care map E11 & covered by M15, M18, and M26)

~~2023-07-21:~~

- ~~• Revised administration table presents information for scope / route / dose more clearly~~

~~2022-06-26:~~

- ~~• Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)~~
- ~~• Revised dosing for calcium (including immediate repeat dosing)~~
- ~~• Reminder to rinse tubing between calcium and bicarbonate administration~~

~~2022-03-13:~~

- ~~• Minor reformatting (removal of change tracking from care map)~~

- ~~Content change (revised indications)~~

~~2021-11-17:~~

- ~~Revised indications~~

~~2021-05-19~~

- ~~Addition of scope of work and standing order statements~~
- ~~Increased administration frequency for insulin~~
- ~~Removal of salbutamol as nebulizers no longer in use~~
- ~~Reformatting~~

~~2020-04-12:~~

- ~~Removal of calcium gluconate from formulary~~
- ~~Consolidation of into one document~~
- ~~Simplification of dosing~~
- ~~Reformatting~~

~~2017-06-20:~~

- ~~Original versions (M10.1, M10.2, M10.3, M10.4)~~

### **M11 - NALOXONE**

2023-07-21:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-26:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-25:

- Addition of scope of work and standing / provisional order statements
- Intranasal administration during COVID now allowed with extended PPE
- Updated dosing information & dosing frequency to allow for titration
- Reformatting

2020-05-25:

- Correction for intranasal dose & IV administration also within PCP scope
- All dosing simplified for ease of recall

2020-05-01

- IM administration now in scope for PCP

2017-06-27:

- Original version

### **M12 — TETRACAINE**

2024-02-13:

- Deleted (removed from ERS formulary)

~~2023-07-23:~~

- ~~Revised administration table presents information for scope / route / dose more clearly~~

~~2022-06-26:~~

- ~~Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement~~

developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Reintroduced

### M13 - HYDROCORTISONE

2023-10-30:

- Correction - asthma added to medication dosing table to align with indications
- IM & SC dosing added for adrenal crisis

2023-07-22:

- Revised administration table presents information for scope / route / dose more clearly

2022-12-07:

- Removal of time qualifier for administration in anaphylaxis
- Addition of asthma as indication

2022-06-26:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Correction of anaphylaxis dosing

2022-03-13:

- Minor reformatting (removal of change tracking from care map)
- Work scope expanded to include paramedics with primary work scope

2021-10-25:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Reformatting

2021-02-04:

- New (replaces methylprednisolone)

### M14 - AMIODARONE

2023-12-13:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-07-17:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-26:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- New indication – stable WCT or VT with prolonged transport
- Revised age categories (adolescent, child & infant combined)
- Revised pediatric single-dose maximum
- Revised ROSC directions including pediatric dosing

2022-03-13:

- Minor reformatting (removal of change tracking from care map)
- Content change (removal of VT & WCT dosing; addition of post-ROSC dosing & high-alert statement)

2021-11-08:

- Addition of scope of work and standing order statements
- Removal of infant dosing
- Addition of dosing for VT and WCT
- Renumbered from 14.1 Reformatting

2020-07-07:

- Clarification of dosing

2017-03-23:

- Original version

#### **M15 – SALBUTAMOL**

2023-09-05:

- Nebulizer may be used in young children who cannot comply with MDI administration
- Revised administration table presents information for scope / route / dose more clearly

2022-06-26:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Addition as temporary treatment of hyperkalemia added

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-11-05:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Removal hyperkalemia as an indication as nebulizers no longer in use
- Clarification / simplification of dosing
- Reformatting

2020-11-05:

- Anaphylaxis indication added
- Removed Combivent nebulizer dosing
- Added reference to M10 for hyperkalemia dosing

2020-05-12:

- Addition of caution about nebulization during COVID-19 pandemic

2019-10-02:

- Original version

#### **M16 - OXYTOCIN**

2023-12-13:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-07-23:

- Revised administration table presents information for scope / route / dose more clearly

2023-05-04:

- Removal of drip rate

2022-06-26:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement

developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-27:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Clarification of indication for continuous infusion
- Addition of high-alert warning
- Reformatting

2017-04-04:

- Original version

### **M17 - KETAMINE**

2023-12-14:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-10-16:

- Revised administration table presents information for scope / route / dose more clearly
- Intranasal route can only be used for extrication
- Not compatible with RL

2023-03-02:

- Removed due to critical shortage

2023-02-22:

- Not compatible with RL

2022-06-26:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2021-11-10:

- Cumulative hourly maximum added
- Footnote regarding caution with hemodynamic compromise

2021-10-25:

- Revised wording for indications to allow for first line use
- Modified dosing & clarification that dosing is based on ideal (not actual) bodyweight

2021-05-18:

- Addition of scope of work and standing order statements
- Intranasal administration now allowed
- Reformatting
- Renamed & renumbered from 17.1

2020-08-26:

- Revised dosing, indications & contraindications
- Inclusion of intranasal dosing at the PCP level

2017-06-13:

- Original version

### M18 - SODIUM BICARBONATE

2023-12-19:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-07-22:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-27:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Pediatric doses combined (ERS units will have only one type of bicarbonate)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-27:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Reformatting

2020-08-26:

- Hyperkalemia indications previously contained in M10.2
- Revised dosing
- Pediatric dosing added

### M21 - NITROGLYCERIN

2023-07-25:

- Revised administration table presents information for scope / route / dose more clearly
- Providers with basic work scope will no longer administer nitroglycerin

2022-06-27:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-04-14:

- Providers with the basic work scope must consult with OLMS
- Clarification of absolute “contraindications” versus “use with caution” conditions

2022-03-15:

- Removal from EMR scope of work
- Removal of IV route
- Minor reformatting (removal of change tracking from care map)

2021-10-27:

- Addition of high alert warning
- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Removal of hypertension as indication
- Extensively revised contraindications
- Addition of IV dosing for ACP
- Reformatting

2017-04-04:

- Original version

#### **M22 - OLANZAPINE**

2023-07-25:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-27:

- Reformatting only (relabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-27:

- Minor reformatting

2021-05-19

- Addition of scope of work and standing order statements
- Reformatting

2020-11-09:

- Reformatting
- Revised indication
- Revised notes

2018-11-26:

- Original version

#### **M24 - MAGNESIUM SULFATE**

2023-12-13:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-10-04:

- Dosing for asthma added

2023-07-25:

- Revised administration table presents information for scope / route / dose more clearly

2023-06-01:

- Dosing information revised to align with D09

2022-06-27:

- Reformatting (relabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- OLMS consultation recommended but not mandatory
- Slower administration rate for preeclampsia / eclampsia

2022-03-13:

- Minor reformatting (removal of change tracking from care map)
- Content change (revised dosing for preeclampsia & eclampsia; additional information regarding magnesium toxicity & treatment)

2021-10-27:

- Minor reformatting



2021-05-19:

- Addition of scope of work and standing order statements
- Revised dosing for pre-eclampsia / eclampsia
- Merging of 24.1 and 24.2
- Reformatting

2017-04-04:

- Original version

#### **M25 - LIDOCAINE**

2023-07-22:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-27:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)
- Content change (infuse over 120 seconds instead of 60 seconds)

2021-10-27:

- Minor reformatting

2021-05-31:

- Addition of scope of work and standing order statements
- Reformatting

2020-04-16:

- Original version

#### **M26 - CALCIUM CHLORIDE**

2024-12-13:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-07-22:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-27:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Removal of calcium gluconate

20-01-13:

- New document

#### **M28 - TRANEXAMIC ACID**

2023-07-17:

- Revised administration table presents information for scope / route / dose more clearly

2023-06-08:

- Addition of nontraumatic hemorrhagic shock to indications

2023-03-11:

- Change pediatric age from > 72 hrs to 1 year
- Note regarding volume adjustment
- Contact OLMS for administration in infants

2022-12-01:

- Addition of PPH to indications
- Administer by infusion instead of slow IV push

2022-06-26:

- Reformatting (relabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Addition of “within three hours of injury” direction to align with current evidence
- Addition of pediatric dosing

2022-03-25:

- Clarification of indications to allow administration without waiting for shock to develop

2022-03-13:

- Minor reformatting (removal of change tracking from care map)
- Content change (removal of epistaxis as an indication due to lack of high-level supporting evidence; compatible with Ringer’s solution; information about rate of administration)

2021-10-28:

- Minor reformatting (replacement of colored boxes with scope of work statement & icons)

2021-05-19:

- Addition of scope of work and standing order statements
- PCP can administer by IO route
- Reformatting

2020-01-07:

- Revised indication
- PCP scope IV administration added
- Formatting

2019-07-10:

- Original version

### **M33 – DIPHENHYDRAMINE**

2024-02-13: (removed from ERS formulary)

- Deleted

~~2023-07-17:~~

- ~~• Revised administration table presents information for scope / route / dose more clearly~~

~~2023-06-10:~~

- ~~• Correction regarding routes of administration~~

~~2022-06-27:~~

- ~~• Reformatting only (relabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)~~

~~2022-03-13:~~

- ~~• Minor reformatting (removal of change tracking from care map)~~

~~2021-10-25:~~

- ~~• Reintroduced with revised indication~~

**M34 - HALOPERIDOL**

2023-07-17:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-27:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-11-25:

- Correction of age in dosing section

2021-10-28:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Reformatting

2021-02-19:

- Revised dosing for adolescent and patients older than 75 years
- Reformatting

2019-04-22:

- Original version

**M37.1 - ACETYLSALICYLIC ACID**

2023-07-22:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-27:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-27:

- Minor reformatting
- Renumbered

2021-05-19:

- Addition of scope of work and standing order statements
- Dose range removed to align with Shared Health acute care protocols
- Reformatting

2020-04-08:

- Reformatted

2018-10-31:

- Original version

**M37.2 - TICAGRELOR**

2023-07-23:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-27:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-27:

- Minor reformatting
- Renumbered

2021-05-19:

- Addition of scope of work and standing order statements
- Addition of potential fibrinolysis to contraindications
- Reformatting

2020-04-07:

- Reformatting

2018-10-31:

- Original version

#### **M38- KETOROLAC**

2023-07-24:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-27:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Dosing for 12 to 24 months added

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-28:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Pregnancy added as contraindication
- IV dosing at PCP level added
- Reformatting

2020-05-01:

- Minimum age for child raised to 2 years & modification of dosing
- IM administration now in scope for PCP
- Additional contraindications

2017-04-04:

- Original version

#### **M39 - ATROPINE**

2023-07-23:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-27:

- Reformatting (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)
- Increased dose to align with 2020 HSF guidelines

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-05-19:

- Addition of scope of work and standing order statements
- Increased adult dosing range for severe bradycardias in adults
- Hypersensitivity added as contraindication
- Caution regarding patients with heart transplants and high-grade blocks
- Reformatting

2017-03-23:

- Original version

#### **M43 - ENOXAPARIN**

2023-12-13:

- Addition of Shared Health Provincial Clinical Standard for high-alert medications

2023-07-24:

- Revised administration table presents information for scope / route / dose more clearly

2022-06-27:

- Reformatting only (reabeled as standing order; work scope identifier moved into header; compliance statement developed into policy A03; new section for age, dosing, route, and scope)

2022-03-13:

- Minor reformatting (removal of change tracking from care map)

2021-10-27:

- Minor reformatting

2021-05-19:

- Addition of scope of work and standing order statements
- Addition of potential fibrinolysis to contraindications
- Renumbered from 43.1
- Reformatting

2020-03-17:

- Intravenous dosing included for patients less than 75 years of age

2018-10-31:

- Original version